2 London-listed stocks I’d buy

I think Glanbia (LON:GLB) and Tate & Lyle (LON:TATE) are two stocks to buy to ride the rising consumer interest in health and nutrition.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

One stock that’s caught my eye is global nutrition group Glanbia (LSE:GLB). It’s enjoying a surge in growth as consumer trends in health, wellness and nutrition gain prominence. The group sells the Optimum Nutrition and SlimFast brands, as well as a popular vitamin and mineral premix. It also has a dairy division, sports nutrition, and speciality non-dairy ingredients. It’s a €4bn company based in Ireland.

Glanbia share price activity

The Glanbia share price has risen 34% year-to-date and is now trading at €14 a share. But it’s down 25% from early 2019. It fell back then after global trade wars impacted earnings. And the share price drop was exacerbated further by Covid-19.

The company has been growing through acquisitions, which continue to improve its future potential. And it’s particularly seeing strong growth across e-commerce. This gives it confidence that its adjusted earnings per share growth will be at the upper end of the growth range it predicted.

But it’s not all rosy. Glanbia has seen a drop in revenues from cheese and it’s also facing a legal dispute over the construction of a new cheese factory in Ireland to which it will supply milk. The National Trust for Ireland (An Taisce) is against the new build for environmental reasons. As the country is trying to reduce emissions to meet the Paris Agreement, they argue a new factory won’t help.

Last month the High Court supported the Glanbia factory build, but An Taisce is appealing this decision.

Would I buy shares in Glanbia?

Glanbia’s price-to-earnings ratio (P/E) is 17, earnings per share (EPS) are 79c while the dividend yield is 1.7%. Between 2015 and 2019, the Glanbia share price consistently sat above where it is today. I think this shows strength and resilience.

I’m tempted to buy shares in Glanbia because it’s providing many of the consumer goods people want today. Nutrition has never been more on the minds of consumers and I think this trend will continue.

Further focus on health and nutrition

The other stock I like is Tate & Lyle (LSE:TATE). It supplies food and beverage ingredients to industrial markets.

As I noted above, there’s a clear trend that consumers want to be healthier, and Tate & Lyle’s got the expertise to make processed foods healthier. Last month Tate announced it’s looking into selling a controlling stake in its commercial sweeteners unit. This would allow it to focus more closely on healthier products through its food and beverage solutions unit. This division makes texturants, stabilisers and low-calorie sweeteners.

I think this seems like a sensible focus for the group and it could benefit shareholders long term. In the past three years, the Tate & Lyle share price has risen 33%. Historically it’s been a volatile investment, but the dividend helps long-term shareholders withstand the low points. It was relegated from the FTSE 100 to the FTSE 250 in 2014 for the 12th time in 23 years. It’s not yet made it back in, but streamlining the business seems like a good way to improve its prospects.

Tate & Lyle has a price-to-earnings ratio (P/E) of 13 and earnings per share (EPS) are 52p. Its dividend yield is around 3.6%.

Glanbia and Tate & Lyle are two stocks I’d buy to follow the health and wellness trend and the e-commerce rise. I own Tate & Lyle shares and would be happy to add more to my Stocks and Shares ISA.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kirsteen owns shares of Tate & Lyle. The Motley Fool UK has recommended Glanbia. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »